Leukocyte response to thymoglobulin or atgam for induction immunosuppression in a randomized, double-blind clinical trial in renal transplant recipients.
D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D004311:Double-Blind Method; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation; D018655:Lymphocyte Count; D016176:T-Lymphocyte Subsets / Q000187:drug effects